Oncolytic Activity of Bacteria used in Cancerous Disease Gene Therapy

Alexandra Valencakova; Elena Hatalova

Authors

Alexandra Valencakova
Elena Hatalova

Keywords:

gene therapy, salmonella spp, clostridium spp, therapeutic strategy

Abstract

Gene therapy is a therapeutic strategy based on using genes as pharmaceuticals. Gene therapy holds promise for treating a wide range of diseases, including cancer, cystic fibrosis, heart disease, diabetes, hemophilia and AIDS. Various types of genetic material are used in gene therapy; double-strained DNA (dsDNA), single strained DNA (ssDNA), plasmid DNA and antisense oligodeoxynucleotides (ASON), adenoviruses, retroviruses, undeveloped/ plasmid DNA and bacteria. The use of bacteria in cancer therapy can be advantageous for various reasons compared to classic chemotherapy or other microorganisms. Bacteria can adhere and invade tumor cells, and they are capable of proliferation and of establishing extracellular colonies. Other than that, their genome length enables them to be recipient to a quantum of exogenous therapeutic genes (for example, enzymes activating precursors and cytokines). The most important thing from the clinical safety view is they can be killed by antibiotics (such as metronidazole) if complications in further treatment arise. For comparison, the capacity of viral vectors is limited and in case of side effects viruses cannot be eliminated by antibiotics.

Downloads

How to Cite

Oncolytic Activity of Bacteria used in Cancerous Disease Gene Therapy. (2016). Global Journal of Medical Research, 16(10), 27-31. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Download Citation

References

Springer Lehouritis P (2013) Bacterialdirected enzyme prodrug therapy. 170(1), 120-31.

Mauchline Minton NP, Brehm Lemmon MJ, Michael Fox M, Giaccia A (1995) Chemotherapeutic tumour targeting using clostridial spores. 17, 357-64.

R. Malmgren, C. Flanigan (1955) Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. 15(7), 473-478.

K. Engelbart, D. Gericke (1964) Oncolysis by clostridia. V. Transplanted tumors of the hamster. 24, 239-242.

(1967) Association of cancer of the breast and acute myelocytic leukemia. 20(7), 1080-8.

D. Gericke, Engelbart (1964) Oncolysis by clostridia. Ii. Experiments on a tumor spectrum with a variety of clostridia in combination with heavy metal. 24, 217-221.

Gericke D, Dietzel F, König W, Rüster I, Schumacher L (1979) Further progress with oncolysis due to apathogenic clostridia. 243(1), 102-12.

F. Dietzel, D. Gericke (1977) Intensification of the oncolysis by clostridia by means of radio-frequency hyperthermy in experiments on animals--dependence on dosage and on intervals (author'stransl). 153(4), 263-266.

Dang LH, Bettegowda C, Huso DL, Kinzler KW (2001) Combination bacteriolytic therapy for the treatment of experimental tumors. 98(26), 5155-1516.

Bettegowda Dang LH, Cheong Agrawal N, Frost Huso D, Greenberger Loganzo F, Pettit Barkoczy J, Khan S, et vascular, antimicrotubule biology, therapy (2004) Targeting vascular and avascular compartments of tumors with C. novyi-NT and antimicrotubule agents. 3(3), 326-337. https://doi.org/10.4161/cbt.3.3.704

Jr Diaz LA, Foss Cheong I, Peters Zhang X, Bettegowda Agrawal N, Liu Karim B, Huang Khan K, Dang Kohli M, et Pharmacologic (2005) Pharmacologic and Toxicologic Evaluation of C. novyi-NT Spores. 88(2), 562-575.

Pennington Theys J, Dubois L (2006) Repeated cycles of Clostridium-directed enzyme prodrug therapy resultin sustained antitumour effects in vivo. 95, 1212-9.

Ahn Liu SC, Kioi M (2008) Optimized Clostridium -Directed Enzyme Prodrug Therapy Improves the Antitumor Activity of the Novel DNA Cross-Linking Agent PR-104. 68(19), 7995-8003. https://doi.org/10.1158/0008-5472.can-08-1698

J. Theys, P. Lambin (2015) Clostridium to treat cancer: dream or reality?. (Suppl 1), S21.

Theys Heap JT, Ehsaan M, safety regression (2014) Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo. 5, 1761-1769.

David Bermudes, Brooks Low, John Pawelek (2000) Tumor-Targeted Salmonella. 465, 57-63. https://doi.org/10.1007/0-306-46817-4

Kenneth Low, Martina Ittensohn, Xiang Luo, Li-Mou Zheng, Ivan King, John Pawelek, David Bermudes (2004) Construction of VNP20009: A Novel, Genetically Stable Antibiotic-Sensitive Strain of Tumor-Targeting Salmonella for Parenteral Administration in Humans. 90, 47-60.

Ittensohn Low KB, Platt Le T, Amoss Sodi S, Carmichael Ash O, Fischer Chakraborty A, Luo Lin SL, Zheng Miller SI, Pawelek King I (1999) Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. 17(1), 37-41.

Gill Toso JF, Marincola Hwu P, Schwartzentruber Restifo NP, Topalian Sherry RM, Stock Yang JC, Morton Freezer LJ, Haworth Seipp C, White Mavroukakis S, Mao MacDonald S, Sznol M (2002) Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. 20(1), 142-52.

Luo Zheng LM, Li Feng M, Ittensohn Le T, Bermudes Trailsmith M, Lin SL (2000) Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector. 12(3), 127-35.

Sodi Pawelek JM, Platt Chakraborty AK, Holden Miller S, Hensel M (2002) Salmonella pathogenicity island-2 and anticancer activity in mice. 9(10), 813-8.

Chiodoni Petrovska L, Bronte Transidico P, Colombo Longhi R, Dougan G (2005) Cancer immuno-therapy based on killing of Salmonella-infected tumor cells. 65(9), 3920-7.

Leschner Westphal K, Loessner Jablonska J (2008) Containment of tumor-colonizing bacteria by host neutrophils. 68(8), 2952-60.

Schreiber Barak Y, Contag Thorne SH, Debeer D (2010) 10:146. 10, 146.

O'Sullivan Morrissey D (2010) 10(1): 3-14. 10(1), 3-14.

K. Bagshawe (1987) Antibody directed enzymes revive anti-cancer prodrugs concept. 56(5), 531-2.

K. Bagshawe (1990) Antibody-directed enzyme/prodrug therapy (ADEPT). 18(5), 750-752.

Tietze LF, PMT. Des (2011) Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT. 17(32), 3527-3547.

Lashkevich Lukashev AN, Koroleva Ivanova OE, Hinkkanen AE (2005) Recombination in circulating Human enterovirus B: independent evolution of structural and non-structural genome regions. 86, 3281-90.

Hailu Satchi-Fainaro R, Summerford Davies JW (2003) PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-betalactamase and HPMA copolymer-C-Dox as a model combination. 14(4), 797-804.

R. Spooner, F. Friedlos, K. Maycroft, S. Stribbling, J. Roussel, J. Brueggen, B. Stolz, T. O'Reilly, J. Wood, A. Matter, R. Marais, C. Springer (2003) A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs. 88(10), 1622-30.

Malkin Knaggs S, Williams Osborn HM (2005) New prodrugs derived from 6- aminodopamine and 4-aminophenol as candidates for melanocyte-directed enzyme prodrug therapy (MDEPT). 3(21), 4002-10.

Schuster Tietze LF, Schuberth Schmuck K (2008) Duocarmycin-based prodrugs for cancer prodrug monotherapy. 16(12), 6312-8.

Spooner Niculescu-Duvaz I, Marais R (1998) 9(1): 4-22. 9(1), 4-22.

Moolten FL (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. 46(10), 5276-81.

Kraemer Finzi L, Noullet Capron C, Penna Goere D, Legagneux Nordlinger B, Emile JF (2011) Improved retroviral suicide gene transfer in colon cancer celll ines after cell synchronization with methotrexate. 30, 92.